Literature DB >> 11008259

Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.

T Balslev1, P Uldall, J Buchholt.   

Abstract

Three girls, two aged 12 years and one aged 17 years with refractory localization-related epilepsy were treated on an add-on basis with tiagabine. At dosages 22.5-30 mg/day (0.45-0.57 mg/kg/day) longstanding non-convulsive status epilepticus was noted in all three patients. The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages. In two cases, tiagabine was withdrawn, whereas it was continued at a lower dosage in one case. This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients. Copyright 2000 European Paediatric Neurology Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11008259     DOI: 10.1053/ejpn.2000.0293

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  6 in total

Review 1.  Treating epilepsy in the elderly: safety considerations.

Authors:  S Arroyo; G Kramer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Tiagabine for acute affective episodes in bipolar disorder.

Authors:  Akshya Vasudev; Karine Macritchie; Sanjay K Rao; John Geddes; Allan H Young
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

3.  Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications.

Authors:  Matthew D Krasowski
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-11

4.  Seizures in a pediatric patient with a tiagabine overdose.

Authors:  Ziad N Kazzi; Chris C Jones; Brent W Morgan
Journal:  J Med Toxicol       Date:  2006-12

Review 5.  Use of second-generation antiepileptic drugs in the pediatric population.

Authors:  Allison M Chung; Lea S Eiland
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 6.  Selected pharmacokinetic issues of the use of antiepileptic drugs and parenteral nutrition in critically ill patients.

Authors:  Muhannad R M Salih; Mohd Baidi Bahari; Arwa Y Abd
Journal:  Nutr J       Date:  2010-12-31       Impact factor: 3.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.